If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-09. Numbers and descriptions here follow the published literature rather than marketing material.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
== Side effects == Phenibut is generally well-tolerated. Possible side effects may include sedation, somnolence, nausea, irritability, agitation, anxiety, dizziness, headache, and allergic reactions such as skin rash and itching. At high doses, motor incoordination, loss of balance, and hangovers may occur. Due to its CNS depressant effects, people taking phenibut should refrain from potentially dangerous activities such as operating heavy machinery. With prolonged use of phenibut, particularly at high doses, the liver and blood should be monitored, due to risk of fatty liver disease and eosinophilia.
== External links == Clinical trial number NCT02447666 for "Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)" at ClinicalTrials.gov
==== Behavior ==== Like in humans, serotonin is involved in regulating behavior in most other vertebrates. This includes not only response and social behaviors, but also influencing mood. Defects in serotonin pathways can lead to intense variations in mood, as well as symptoms of mood disorders, which can be present in more than just humans.
Due to PTT activity in hypoxic environments, it may be also used on more developed tumors than PDT. Low-temperature PTT (≤ 45 °C) for treatment of infections is also a possibility when combined with an antibiotic compound due to heat's proportionality with membrane permeability - a hotter environment causes heightened membrane permeability, which thus allows the drug into the cell. This would reduce/eliminate the impact on human cell viability, and aiding in antibiotic accumulation within the target cell may assist in restoring activity in antibiotics that pathogens had developed resistance to. PTT is typically seen to have improved antimicrobial and wound healing activity when combined with an additional mechanism of action through PDT or added antibiotic compounds in the application.
== StAR-independent steroidogenesis == While loss of functional StAR in the human and the mouse catastrophically reduces steroid production, it does not eliminate all of it, indicating the existence of StAR-independent pathways for steroid generation. Aside from the human placenta, these pathways are considered minor for endocrine production. It is unclear what factors catalyze StAR-independent steroidogenesis. Candidates include oxysterols which can be freely converted to steroid and the ubiquitous MLN64.
Sources: en.wikipedia.org
=== Premixed === Appropriate patient selection is an essential component of successful premixed insulin therapy. Kalra was the lead author of a comprehensive review developed with collaborators from more than 25 countries. He has also published extensively on the use of premixed insulin during Ramadan and on its role in special situations, from initiation to intensification. He has also published updates on premixed insulins, including real-world evidence regarding newer co-formulations.
Sample preparation for mass spectrometry is used for the optimization of a sample for analysis in a mass spectrometer (MS). Each ionization method has certain factors that must be considered for that method to be successful, such as volume, concentration, sample phase, and composition of the analyte solution. Quite possibly the most important consideration in sample preparation is knowing what phase the sample must be in for analysis to be successful. In some cases the analyte itself must be purified before entering the ion source. In other situations, the matrix, or everything in the solution surrounding the analyte, is the most important factor to consider and adjust. Often, sample preparation itself for mass spectrometry can be avoided by coupling mass spectrometry to a chromatography method, or some other form of separation before entering the mass spectrometer. In some cases, the analyte itself must be adjusted so that analysis is possible, such as in protein mass spectrometry, where usually the protein of interest is cleaved into peptides before analysis, either by in-gel digestion or by proteolysis in solution.
Individuals in professions such as pilots, nuclear physicians, and nuclear power plant workers are regularly exposed to ionizing radiation. In Germany, over 400,000 workers undergo occupational radiation monitoring to safeguard against the harmful effects of radiation. Approximately 70,000 individuals employed across various industries possess a radiation pass (distinct from an X-ray pass - see below). Individuals who may receive an annual effective dose of more than 1 millisievert during their work are required to undergo radiation protection monitoring. In Germany, the effective dose from natural radiation is 2.1 millisieverts per year. Radiation dose is measured using dosimeters, and the occupational dose limit is 20 millisieverts per year. Monitoring also applies to buildings, plant components or (radioactive) substances. These are exempted from the scope of the Radiation Protection Ordinance by a special administrative act, the exemption in radiation protection. To this end, it must be ensured that the resulting radiation exposure for an individual member of the public does not exceed 10 μSv per calendar year and that the resulting collective dose does not exceed 1 person sievert per year.
=== Commercial applications === According to a 2010 survey, the three primary uses of the 26,000 low-energy particle accelerators operating worldwide are radiotherapy (44%), ion implantation (41%), and industrial processing (9%). HVEC made foundational contributions to all three. The company's compact Van de Graaff generators were among the first artificial radiation sources commercially available for cancer treatment. Radiation physicist Milford Schulz called them "truly milestones in the progress of radiotherapy." The first medical linear accelerator—now the dominant technology in cancer treatment—was assembled at Stanford using a retrofitted HVEC machine. Ion implantation, pioneered at HVEC's Ion Physics Corporation, became standard practice in semiconductor manufacturing by the late 1970s. The technique enabled MOS integrated circuits that dominate modern electronics. Radiation crosslinking, developed at Electronized Chemicals Corporation, produced heat-shrink tubing and films now ubiquitous in electrical wiring and food packaging.
Sources: en.wikipedia.org
=== August === 1 August Tony Brien, 54, footballer (Leicester City, Chesterfield, Rotherham United, West Bromwich Albion, Mansfield Town, Chester City, Hull City). John Madigan, 76, hurler (Charleville, Avondhu) and rugby union player (UL Bohemians, Munster). 4 August – Colin O'Daly, 70, chef. 9 August – Art McRory, 82, Gaelic footballer (Dungannon, Tyrone senior team) and manager (Tyrone minor and senior teams). Born in Northern Ireland. 15 August – Liam McDaid, 78, Roman Catholic prelate. 23 August – Chryss Goulandris, 73, businesswoman, horse breeder and wife of Tony O'Reilly. Born in the United States.
Ontogeny The development of an individual organism, particularly the growth and differentiation of the nervous system from embryo to adult. Operculum (brain) A part of the cerebral cortex that covers the insula. It includes portions of the frontal, temporal, and parietal lobes. Opsin A light-sensitive protein found in photoreceptor cells of the retina. Plays a key role in the molecular detection of light in vision. Optic chiasm The point at which the optic nerves from both eyes partially cross, allowing visual information from each eye to be processed in both hemispheres of the brain. Optic nerve (Cranial Nerve II) A cranial nerve that transmits visual information from the retina to the lateral geniculate nucleus of the thalamus. Optic tract The continuation of the optic nerve fibers after the optic chiasm; carries visual information to the thalamus and midbrain. Optogenetics A technique that uses light-sensitive proteins to control the activity of genetically targeted neurons. Widely used in neuroscience research to study circuit function. Orbitofrontal cortex A prefrontal brain region involved in decision-making, reward processing, and emotional regulation. Dysfunction is linked to addiction and impulsivity. Organ of Corti The sensory organ within the cochlea that contains hair cells and is responsible for converting sound vibrations into neural signals. Orientation column A vertical column of neurons in the visual cortex that respond to lines of the same orientation. Part of the brain’s system for processing visual features.
=== February === 1 February – Scottish Water confirms that water bills will increase by 8.8% from April. Honshu, a seven-year-old male Japanese macaque who escaped from the Highland Wildlife Park at Kincraig, is recaptured after five days on the run. 3 February – A bus driver, subsequently named as Keith Rollinson, dies in hospital at Elgin following an assault at a bus station in the town the previous evening. A 15-year-old boy is subsequently arrested and charged with murder. Transport Scotland has put forward proposals for road tunnels linking parts of the Western Isles, and linking Mull to the mainland. 4 February – The Scottish Information Commissioner, which oversees Scotland's freedom of information laws, launches a probe into the Scottish Government's use of informal messaging such as WhatsApp after "significant practice concerns" were raised by the UK COVID-19 Inquiry. The Met Office issues a yellow warning for floods for western and northern Scotland as the country experiences heavy rainfall. 6 February – Elena Whitham resigns from the post of Minister for Drugs and Alcohol Policy for health reasons. 8 February – Michael Matheson resigns as Scotland's Health Secretary ahead of the publication of a report into £11,000 of data roaming charges accrued by his Parliamentary iPad. He is replaced by Neil Gray. The Scottish Government announces a rise in the minimum unit price for alcohol from 50p to 65p from April, subject to parliamentary approval. Edinburgh City Council says that 200 people have been fined since it introduced a ban on pavement parking on 29 January.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.